Mark Fuller

Title: Mark Fuller: Innovator in Biochemical Patents

Introduction

Mark Fuller is an accomplished inventor based in Seatac, Washington. He has made significant contributions to the field of biochemistry, holding three patents that showcase his innovative spirit and dedication to scientific advancement.

Latest Patents

One of his latest patents is titled "Inhibition of COX-2 and/or 5-LOX activity by fractions isolated or derived from hops." This patent discloses a natural formulation of compounds derived from hops that inhibit the activity of cyclooxygenase-2 (COX-2) and/or 5-lipoxygenase (5-LOX). These formulations may be administered to mammals to treat or inhibit pathological conditions associated with the activity of these enzymes. Another notable patent is "Phage displayed cell binding peptides." This disclosure provides the construction, expression, and selection of mutated genes that encode novel Trp cage polypeptides with desirable binding properties. The targets of these polypeptides may include proteins, other biological macromolecules, and various organic and inorganic substances.

Career Highlights

Throughout his career, Mark Fuller has worked with several prominent companies, including Moderna, Inc. and Metaproteomics, LLC. His work in these organizations has allowed him to apply his innovative ideas in practical settings, contributing to advancements in biotechnology and pharmaceuticals.

Collaborations

Mark has collaborated with notable professionals in his field, including Richard E. Herman and Ekaterina G. Makienko. These collaborations have further enriched his research and development efforts.

Conclusion

Mark Fuller is a distinguished inventor whose work in biochemistry has led to significant advancements in the understanding and application of natural compounds. His patents reflect a commitment to innovation and the potential for improving health outcomes through scientific research.